GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (NAS:SNGX) » Definitions » Cyclically Adjusted Revenue per Share

Soligenix (Soligenix) Cyclically Adjusted Revenue per Share : $0.00 (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Soligenix Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Soligenix's adjusted revenue per share for the three months ended in Dec. 2023 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Soligenix's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Soligenix was -2.20% per year. The lowest was -14.60% per year. And the median was -10.10% per year.

As of today (2024-05-02), Soligenix's current stock price is $0.4048. Soligenix's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.00. Soligenix's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Soligenix was 4.89. The lowest was 0.07. And the median was 0.72.


Soligenix Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Soligenix's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soligenix Cyclically Adjusted Revenue per Share Chart

Soligenix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.77 38.02 - 27.53 -

Soligenix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.53 - - - -

Competitive Comparison of Soligenix's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Soligenix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Soligenix's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Soligenix's Cyclically Adjusted PS Ratio falls into.



Soligenix Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Soligenix's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/129.4194*129.4194
=0.000

Current CPI (Dec. 2023) = 129.4194.

Soligenix Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 6.902 99.695 8.960
201406 10.662 100.560 13.722
201409 20.203 100.428 26.035
201412 8.485 99.070 11.084
201503 5.006 99.621 6.503
201506 6.395 100.684 8.220
201509 20.529 100.392 26.465
201512 16.158 99.792 20.955
201603 12.124 100.470 15.617
201606 14.495 101.688 18.448
201609 12.921 101.861 16.417
201612 5.941 101.863 7.548
201703 3.647 102.862 4.589
201706 2.657 103.349 3.327
201709 3.633 104.136 4.515
201712 2.000 104.011 2.489
201803 1.335 105.290 1.641
201806 2.346 106.317 2.856
201809 0.913 106.507 1.109
201812 0.640 105.998 0.781
201903 0.531 107.251 0.641
201906 0.863 108.070 1.033
201909 0.707 108.329 0.845
201912 0.408 108.420 0.487
202003 0.542 108.902 0.644
202006 0.163 108.767 0.194
202009 0.257 109.815 0.303
202012 0.143 109.897 0.168
202103 0.013 111.754 0.015
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.017 121.301 0.018
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.069 125.222 0.071
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Soligenix  (NAS:SNGX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Soligenix was 4.89. The lowest was 0.07. And the median was 0.72.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Soligenix Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Soligenix's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Soligenix (Soligenix) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (NAS:SNGX) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Executives
Timothy R. Cote director 3529 TILDEN STREET, NW, WASHINGTON DC 20008
Richard Straube officer: CMO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Christopher Schaber director, officer: Chairman, CEO and President 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Jonathan L. Guarino officer: Chief Financial Officer 100 WELLESLEY WAY, FREEHOLD NJ 07728
Oreola Donini officer: CSO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Robert J. Rubin director 7901 SPRINGER ROAD, BETHESDA MD 20817
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Mark E. Pearson director, 10 percent owner 3031 TISCH WAY, SUITE 505, SAN JOSE CA 95128
Preta Martina Cavazza other: Former 10% Owner VIA SUDAFRICA 20, ROME L6 00144
Enrico Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Francesca Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144